{"id":4259,"date":"2025-07-10T11:02:59","date_gmt":"2025-07-10T09:02:59","guid":{"rendered":"https:\/\/mikrobiomik.net\/we-have-launched-a-e500000-round-on-capital-cell\/"},"modified":"2025-07-12T11:17:27","modified_gmt":"2025-07-12T09:17:27","slug":"we-have-launched-a-e500000-round-on-capital-cell","status":"publish","type":"post","link":"https:\/\/mikrobiomik.net\/en\/we-have-launched-a-e500000-round-on-capital-cell\/","title":{"rendered":"We have launched a \u20ac500,000 round on Capital Cell"},"content":{"rendered":"[vc_row type=”in_container” full_screen_row_position=”middle” column_margin=”default” column_direction=”default” column_direction_tablet=”default” column_direction_phone=”default” scene_position=”center” text_color=”dark” text_align=”left” row_border_radius=”none” row_border_radius_applies=”bg” overflow=”visible” overlay_strength=”0.3″ gradient_direction=”left_to_right” shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_tablet=”inherit” column_padding_phone=”inherit” column_padding_position=”all” column_element_direction_desktop=”default” column_element_spacing=”default” desktop_text_alignment=”default” tablet_text_alignment=”default” phone_text_alignment=”default” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_backdrop_filter=”none” column_shadow=”none” column_border_radius=”none” column_link_target=”_self” column_position=”default” gradient_direction=”left_to_right” overlay_strength=”0.3″ width=”1\/1″ tablet_width_inherit=”default” animation_type=”default” bg_image_animation=”none” border_type=”simple” column_border_width=”none” column_border_style=”solid”][vc_column_text css=”” text_direction=”default”]\n

10\/07\/2025<\/p>\n

We have launched a \u20ac500,000 round on Capital Cell to launch the first oral microbiotherapy in Europe<\/h2>\n

\"A<\/p>\n

We have recently launched a \u20ac500,000 investment round through Capital Cell, the leading equity crowdfunding platform in biomedicine.<\/h2>\n

The goal: to bring the first oral microbiota-based therapy, MBK-01, to the European market<\/strong>, a life-saving solution that restores the intestinal ecosystem with the potential to transform the treatment of recurrent infections such as Clostridioides difficile<\/em> (CDI), decompensated liver cirrhosis, and acute diverticulitis.<\/p>\n

A rethinking of medicine<\/h2>\n

\u2018We have been using antibiotics to kill bacteria for a century. Now we know that, in many cases, the key is not to eliminate them, but to maintain them,\u2019<\/strong> explains Patricia del R\u00edo, CEO of Mikrobiomik.
\n\u2018MBK-01 does not destroy: it rebuilds. And that opens up a new way of treating chronic infections, providing effective solutions for patients and curbing antimicrobial resistance.\u2019<\/strong><\/p>\n

The impact is remarkable:<\/p>\n